ANZCHOG Children’s Cancer Clinical Trials Repository

The ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) aims to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.

Each trial listed contains basic information and a link to the relevant national or internal clinical trial registry such as ANZCTR, clinicaltrials.gov and EU Clinical Trials Register.

Trial eligibility is extensive and often varies depending on medical history and current health status. Your child’s oncologist and medical team are the best people to talk to about trial eligibility. They will be able to provide personalised advice based on your individual circumstances.

Filter by

Open
  • Trial Stage
  • Closed to Recruitment
  • Completed
  • In Development
  • Open
  • Preparing to Open
  • Temporarily closed to recruitment
Location
  • Location
  • New Zealand
  • NSW
  • QLD
  • SA
  • TAS
  • VIC
  • WA
Disease Type
  • Disease Type
  • Bone Cancers (Ewing Sarcoma/Osteosarcoma)
  • Brain and other Central Nervous System (CNS) Tumours
  • Germ Cell Tumours
  • Hodgkin Lymphoma
  • Kidney (Renal) Tumours
  • Leukaemia
  • Liver tumours
  • Neuroblastoma
  • Non-Hodgkin Lymphoma
  • Other
  • Soft Tissue Sarcomas
Disease Stage
  • Disease Stage
  • Newly diagnosed
  • Other
  • Relapsed/Recurrent
reset filter
Study Title Protocol ID Condition/s Diagnosis Stage Location Links Status Trial Open Date Trial Close Date Sites Study Type Phase Age Eligibility ANZCTR International registry ID's
AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones AALL1631 Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia
New diagnosis NSW / QLD / WA External
Registry ≫
Open 19/04/2018 Treatment Phase 3 1 year to 21 years at diagnosis NCT03007147
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) AALL1731 B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
New diagnosis NSW / VIC / WA / SA / NZ External
Registry ≫
Open 15/10/2019 Treatment Phase 3 1 year to 31 Years NCT03914625
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy AALL1732 B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Central Nervous System Leukemia
Mixed Phenotype Acute Leukemia
Testicular Leukemia
New Diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 28/10/2019 Treatment Phase 3 1 Year to 24 Years NCT03959085
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome AAML1531 Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm
New diagnosis NSW / VIC / WA / NZ External
Registry ≫
Open 03/11/2015 Treatment Phase 3 90 days to 4 years NCT02521493
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) AAML18P1 Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive On treatment VIC / WA External
Registry ≫
Open 15/07/2019 Treatment Phase 2 up to 25 years NCT03817398
ACNS1422: A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients ACNS1422 Medulloblastoma New diagnosis NSW / WA / SA External
Registry ≫
Open Treatment Phase 2 3 years to 22 years at the time of enrollment NCT02724579
ACT001-AU-002: A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors ACT001-AU-002 Advanced brain tumour
Advanced solid tumour
Relapse/refractory NSW / WA External
Registry ≫
Open 18/09/2019 Treatment Phase 1 1 Year to 21 Years ACTRN12618001934235
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors AGCT1531 Germ Cell Tumour New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 08/05/2017 Treatment Phase 3 Various depending on risk group & consult protocol NCT03067181
ALLELE: Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy ALLELE (ATA129-EBV-302) EBV post transplant Refractory NSW / VIC / WA External
Registry ≫
Open 29/12/2017 Treatment Phase 3 no limits NCT03394365
ALTE03N1: Key Adverse Events After Childhood Cancer ALTE03N1 Childhood Malignant Neoplasm Previously treated QLD / WA / SA External
Registry ≫
Open 24/03/2004 Observational Not applicable up to 21 Years NCT00082745
ALTE07C1: Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer ALTE07C1 All Tumour Types
New diagnosis
Relapse/refractory
QLD / VIC / WA / SA / NZ External
Registry ≫
Open 15/09/2008 Psycho-social Not applicable 3 Years to 21 Years NCT00772200
ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy ALTE11C2 Hodgkin Lymphoma in Remission
Leukemia in Remission
Lymphoblastic Lymphoma
Osteosarcoma
Recurrent Leukemia
Recurrent Lymphoma
Recurrent Malignant Neoplasm
Previously treated WA External
Registry ≫
Open 05/08/2013 Late Effects Not applicable no limits NCT01790152
ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study ALTE15N2 Recurrent Neuroblastoma Relapse/refractory WA / NZ External
Registry ≫
Open 05/06/2017 Late Effects Not applicable 5 Years to 50 Years NCT03057626
ANBL1821: A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma ANBL1821 Solid tumours (Neuroblastoma) Relapse/refractory NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 28/05/2019 Treatment Phase 2 1 Year and older NCT03794349
ANZUP 1302: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours ANZUP 1302 Germ Cell Tumour New diagnosis QLD / NZ External
Registry ≫
Open 01/02/2014 Treatment Phase 3 11 Years to 45 Years NCT02582697
APEC14B1: Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study APEC14B1 All Paediatric Cancer Types NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 26/10/2015 Registry Not applicable up to 25 years NCT02402244
AREN03B2: Renal Tumors Classification Biology and Banking Study AREN03B2 Renal tumours Newly diagnosed NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 27/06/2007 Observational Not applicable up to 29 Years NCT00898365
AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) AREN1921 Anaplastic Kidney Wilms Tumor
Recurrent Kidney Wilms Tumor
Stage II Kidney Wilms Tumor
Stage III Kidney Wilms Tumor
Stage IV Kidney Wilms Tumor
New Diagnosis
Relapse
NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 18/09/2020 Treatment Phase 2 up to 30 Years NCT04322318
ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors ARST1921 Desmoid Fibromatosis
Recurrent Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
New Diagnosis
Relapse
WA External
Registry ≫
Open 21/09/2020 Treatment Phase 2 12 Months to 18 Years NCT04195399
ASSET: Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia ASSET Acute Lymphoblastic Leukaemia (ALL) Previously treated NSW / VIC / WA / SA / NZ External
Registry ≫
Open 20/08/2015 Registry Not applicable up to 18 years
Developing genetically modified TCells for the treatment of paediatric solid tumours CARTpaedST Solid tumours New diagnosis NSW Open 08/04/2018 Treatment Phase 1 up to 18 years
CCTL019A2205B: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy CCTL019A2205B Patients who have received CAR-T cell therapy Previously treated VIC External
Registry ≫
Open 02/11/2015 Observational Not applicable Child, Adult, Older Adult NCT02445222
CFZ2008: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia CFZ2008 / 20140106 Acute Lymphoblastic Leukaemia (ALL) Relapse/refractory NSW / QLD / VIC / WA External
Registry ≫
Open 10/09/2015 Treatment Phase 1/2 1 Month to 21 Years NCT02303821
CONNECT1903: A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion CONNECT1903 High Grade Glioma (HGG)
Diffuse Intrinsic Pontine Glioma (DIPG)
New diagnosis NSW / QLD / WA External
Registry ≫
Open 08/04/2021 Treatment Pilot up to 21 years NCT04655404
FIREFLY: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma DAY101-001 (FIREFLY) Low-grade Glioma Relapse/refractory NSW / QLD / VIC / WA / SA External
Registry ≫
Open 17/03/2021 Treatment Phase 2 6 Months to 25 Years NCT04775485
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue HeadStart4 Medulloblastoma
Central Nervous System Embryonal Tumors
Newly diagnosed NZ External
Registry ≫
Open 01/09/2015 Treatment Phase 4 up to 10 Years NCT02875314
HoTRODS: Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies HoTRODS Diffuse Pontine Glioma
Diffuse Midline Glioma
High grade glioma
New Diagnosis
Relapse
NSW / WA External
Registry ≫
Open 17/07/2012 Observational Not applicable no limits ACTRN12612001183875
iMATRIX: A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available iMATRIX (GO42286) ALK Fusion-positive Solid or CNS Tumors Relapse/refractory NSW / VIC External
Registry ≫
Open 26/07/2021 Treatment Phase 1/2 up to 17 Years NCT04774718
INFORM2: Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies INFORM2 NivEnt CNS Tumour
Solid Tumour
Recurrent/ refractory
NSW / VIC / WA External
Registry ≫
Open 26/07/2019 Treatment Phase 1/2 6 Years to 21 Years NCT03838042
LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis LCH-IV Langerhans Cell Histiocytosis New diagnosis NSW / QLD / VIC / WA / NZ / TAS External
Registry ≫
Open 14/04/2014 Treatment Phase 3 up to 18 years NCT02205762
LOXO-RET-18036: A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours LOXO-RET-18036 Medullary Thyroid Cancer
Infantile Myofibromatosis
Infantile Fibrosarcoma
Papillary Thyroid Cancer
Soft Tissue Sarcoma
Relapse/ refractory NSW / VIC External
Registry ≫
Open 01/07/2019 Treatment Phase 1/2 6 months to 21 years NCT03899792
LOXO-TRK-15003: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors LOXO-TRK-15003 Solid Tumors Harboring NTRK Fusion New diagnosis
Relapse/ refractory
NSW / VIC / WA External
Registry ≫
Closed to Recruitment, Open 11/09/2017 Treatment Phase 1/2 up to 21 years NCT02637687
NB SCI Registry: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI) NB SCI Registry Neuroblastic Tumors NSW / QLD / VIC / WA / SA / TAS External
Registry ≫
Open 01/04/2015 Registry Not applicable up to 18 Years NCT02559804
LGG Avastin: A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma OZM-063 (LGG Avastin) Low Grade Glioma New diagnosis
Relapse/ refractory
NSW / QLD / VIC / WA / SA External
Registry ≫
Open 29/05/2018 Treatment Phase 2 6 months to 18 years old NCT02840409
P3505: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients P3505 Haematological diseases New Diagnosis
Relapse/Refractory
QLD / VIC External
Registry ≫
Open 17/06/2020 Supportive Care Phase 1 3 months to 18 years ACTRN12620000141943
AALL1922: A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation Ponatinib-1501 /AALL1922 Leukaemia (ALL) Relapse/ refractory QLD / VIC / WA External
Registry ≫
Open 21/02/2021 Treatment Phase 1/2 1 Year to 21 Years NCT04501614
PRISM: PRecISion Medicine for Children with Cancer PRISM All Paediatric Cancer Types New Diagnosis
Relapse/ Refractory
NSW / VIC / WA External
Registry ≫
Open 05/09/2017 Biology Biology up to 21 years NCT03336931
R3ACT Fungal: A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation R3ACT Fungal Invasive Fungal Disease Newly diagnosed
Relapsed/Refractory
NSW External
Registry ≫
Open 19/08/2019 Treatment Phase 1 1 Years to 80 Years ACTRN12618001540202
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma ReRAD Recurrent or Progressive Diffuse Intrinsic Pontine Glioma Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 15/04/2017 Treatment Phase 2 up to 17 years NCT03126266
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma RG_13-277 (rEECur) Ewings sarcoma Relapse/ refractory NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 03/04/2018 Treatment Phase 2/3 4 years to 50 years ACTRN12618001825246
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma RG_17-427 (FaR-RMS) Rhabdomyosarcoma Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 17/09/2020 Treatment Phase 1 no limits NCT04625907
T2017-002: A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) T2017-002 Acute Lymphoblastic Leukaemia (ALL) Relapsed/ refractory NSW / VIC External
Registry ≫
Open 12/02/2019 Treatment Phase 1/2 1 Year to 21 Years NCT03817320
TiNT: A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas TiNT Solid tumours Relapsed/ refractory NSW / VIC / WA / SA / NZ / TAS External
Registry ≫
Open 01/03/2021 Treatment Phase 2 3 Months to 25 Years ACTRN12620001229965
TOTAL 17: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma TOTAL 17 Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Newly diagnosed VIC External
Registry ≫
Open 01/12/2021 Treatment Phase 2/3 1 Year to 18 Years NCT03117751
TPX-0005-07: A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations TPX-0005-07 Solid tumours Relapsed/ refractory NSW / QLD / WA External
Registry ≫
Open 20/03/2020 Treatment Phase 1/2 up to 25 years NCT04094610
EFC16295: A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A EFC16295 Hemophilia A Recurrent/ refractory QLD External
Registry ≫
Open 19/02/2021 Treatment Phase 3 up to 12 years NCT04759131
ACNS2021: A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor ACNS2021 Central Nervous System Nongerminomatous Germ Cell Tumor
Choriocarcinoma
Embryonal Carcinoma
Immature Teratoma
Malignant Teratoma
Mixed Germ Cell Tumor
Pineal Region Germ Cell Tumor
Pineal Region Immature Teratoma
Pineal Region Yolk Sac Tumor
Suprasellar Germ Cell Tumor
Newly diagnosed NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 04/06/2021 Treatment Phase 2 3 Years to 30 Years NCT04684368
DIPG: International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository DIPG Diffuse Intrinsic Pontine Glioma (DIPG)
Diffuse Midline Glioma, H3 K27M-Mutant
Diffuse Midline Glioma
NSW / QLD / WA / NZ External
Registry ≫
Open 30/06/2012 Registry Not applicable Child, Adult, Older Adult NCT03101813
PPB DICER: International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions PPB DICER Pleuropulmonary Blastoma
Wilms Tumor
Pineoblastoma
Neuroblastoma
Embryonal Rhabdomyosarcoma
NSW / WA External
Registry ≫
Open 06/12/2015 Registry Not applicable Child, Adult, Older Adult NCT03382158
Bu4Day-PK-2016: Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study Bu4Day-PK-2016 Haematopoietic Stem Cell Transplant Newly diagnosed
Relapsed/refractory
NSW / QLD / WA External
Registry ≫
Open 29/05/2017 Observational Pilot up to 18 years ACTRN12617000227392
ACOR: Australian Cardio-Oncology Registry ACOR All paediatric cancer types Newly diagnosed NSW / VIC / WA / SA / TAS Open 01/09/2018 Registry Not applicable up t 35 Years
PREDICT: Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients PREDICT Neoplastic Syndromes, Hereditary
Cancer
Genetic Predisposition to Disease
Newly diagnosed NSW External
Registry ≫
Open 08/03/2021 Observational Not applicable up to 21 years NCT04903782
ALL Registry: Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research Acute Leukaemia Registry Leukaemia NSW / QLD / VIC / WA / TAS Open 01/04/2019 Registry Not applicable Child, Adult, Older Adult
BLU-285-3101: A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling BLU-285-3101 Solid tumours
CNS Tumours
Relapse/refractory
NSW / VIC External
Registry ≫
Open 14/10/2022 Treatment Phase 1/2 2 Years to 17 Years NCT04773782
ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma ANHL1931 Primary Mediastinal Large B-Cell Lymphoma Newly Diagnosed NSW / QLD / VIC / WA External
Registry ≫
Open 07/06/2021 Treatment Phase 3 2 Years and older NCT04759586
ARST2031: A Randomized Phase 3 Trial of Vinorelbine Dactinomycin and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) ARST2031 Rhabdomyosarcoma Newly diagnosed NSW / VIC / WA External
Registry ≫
Open 12/09/2023 Treatment Phase 3 up to 50 Years NCT04994132
MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients MetMED Medulloblastoma Previously treated NSW / VIC / WA External
Registry ≫
Open 28/09/2022 Treatment Phase 3 7 years to 17 years ACTRN12622000045718
M20-429: A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms M20-429 Non-Hodgkin Lymphoma Relapsed/refractory NSW / VIC / WA External
Registry ≫
Open 29/09/2022 Treatment Phase 1/2 1 Year to 21 Year5 NCT05206357
PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression PNOC022 Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Newly diagnosed
Relapsed/Refractory
NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 18/08/2022 Treatment Phase 1/2 2 Years to 39 Years NCT05009992
CA224-069: A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma CA224-069 Non-Hodgkin Lymphoma Relapsed/Refractory NSW / QLD / WA External
Registry ≫
Open 01/11/2022 Treatment Phase 1/2 up to 30 Years NCT05255601
CONNECT2108: Phase 2 Study of the MEK inhibitor MEKTOVI® (binimetinib) for the treatment of Pediatric Adamantinomatous Craniopharyngioma CONNECT2108 Adamantinomatous Craniopharyngioma Relapsed/refractory NSW / QLD / WA External
Registry ≫
Open 08/05/2023 Treatment Phase 2 1 Year to 25 Years NCT05286788
CO43810: A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma CO43810 Mature B-Cell Non-Hodgkin Lymphoma Relapsed/refractory QLD / WA External
Registry ≫
Open 16/11/2022 Treatment Phase 1/2 6 Months to 30 Years NCT05533775
D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours D0816C00025 Solid Tumours Relapsed/refractory NSW / WA External
Registry ≫
Open 01/11/2022 Treatment Phase 1 0 Years to 18 Years NCT04236414
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Pediatric Adamantinomatous Craniopharyngioma CONNECT1905 Adamantinomatous Craniopharyngioma Relapsed/refractory NSW / QLD / WA External
Registry ≫
Open 19/12/2022 Treatment Phase 2 1 Year to 25 Years NCT05233397
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) ACNS1821 Anaplastic Astrocytoma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
Glioblastoma, Not Otherwise Specified
Malignant Glioma
Newly diagnosed NSW / QLD / VIC / NZ External
Registry ≫
Open 05/05/2022 Treatment Phase 1/2 12 Months to 21 Years NCT05099003
APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations APEC1621F All paediatric cancer types Relapsed/refractory WA External
Registry ≫
Open 17/04/2018 Treatment Phase 2 12 Months to 21 Years NCT03213652
ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma ARET2121 Bilateral Retinoblastoma
Childhood Intraocular Retinoblastoma
Group D Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Newly diagnosed WA External
Registry ≫
Open Treatment Phase 2 up to 18 Years NCT05504291
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma AOST2031 Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Newly diagnosed NSW / VIC / WA / NZ External
Registry ≫
Open 13/01/2023 Treatment Phase 3 up to 50 Years  NCT05235165
ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma ARST2032 Embryonal Rhabdomyosarcoma
Fusion-Negative Alveolar Rhabdomyosarcoma
Spindle Cell/Sclerosing Rhabdomyosarcoma
Newly diagnosed NSW / WA / NZ External
Registry ≫
Open 09/12/2022 Treatment Phase 3 up to 21 years NCT05304585
ASCT2031: A Multi-Center Phase 3 Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children Adolescents and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS) ASCT2031 Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Newly diagnosed NSW External
Registry ≫
Open 12/12/2023 Treatment Phase 3 6 Months to 22 Years NCT05457556
Firefly-2: A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy Firefly-2 Low-Grade Glioma Newly diagnosed NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 19/05/2023 Treatment Phase 3 up to 25 Years NCT05566795
APAL2020D: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML APAL2020D Acute myeloid leukemia Relapsed/refractory QLD / VIC / WA / NZ External
Registry ≫
Open 01/10/2022 Treatment Phase 3 29 Days to 21 Years NCT05183035
TAK-620-2004: A Phase 3 Open-label Single-arm Repeated-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) TAK-620-2004 Cytomegalovirus (CMV) Previously treated NSW / QLD / WA External
Registry ≫
Open 29/05/2024 Treatment Phase 3 up to 17 Years NCT05319353
APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias APAL2020SC Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy
Juvenile Myelomonocytic Leukemia
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome Post Cytotoxic Therapy
Myeloid Leukemia Associated With Down Syndrome
Relapsed/refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 30/11/2021 Observational Not applicable up to 22 Years NCT04726241
ZERO2: Precision Medicine for Every Child With Cancer ZERO2 All paediatric cancer types
Newly diagnosed
Relapsed/Refractory
NSW / QLD / VIC / WA / SA / NZ / TAS External
Registry ≫
Open 16/12/2022 Observational Not applicable 0 Years to 25 Years NCT05504772
LTS16294: A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A LTS16294 Hemophilia A
Previously treated NSW / QLD / WA External
Registry ≫
Open 23/02/2022 Treatment Phase 3 Child, Adult, Older Adult NCT04644575
HR NBL2: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) HR NBL2 Neuroblastoma Newly diagnosed NSW / VIC External
Registry ≫
Open 31/03/2023 Treatment Phase 3 up to 20 years NCT04221035
CAMPFIRE: A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma CAMPFIRE- J1S-MC-JP04 Ewing Sarcoma
Neoplasm Metastasis
Relapsed/refractory NSW / VIC External
Registry ≫
Open 10/09/2022 Treatment Phase 2 1 Year to 39 Years NCT05440786
PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PEPN2121 Atypical Teratoid/Rhabdoid Tumor
Epithelioid Sarcoma
Kidney Medullary Carcinoma
Malignant Solid Neoplasm
Poorly Differentiated Chordoma
Recurrent Atypical Teratoid/Rhabdoid Tumor
Recurrent Chordoma
Recurrent Epithelioid Sarcoma
Recurrent Kidney Medullary Carcinoma
Recurrent Malignant Solid Neoplasm
Recurrent Rhabdoid Tumor
Refractory Atypical Teratoid/Rhabdoid Tumor
Refractory Chordoma
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Rhabdoid Tumor
Newly diagnosed
Relapsed/Refractory
NSW / QLD External
Registry ≫
Open 16/08/2024 Treatment Phase 1/2 12 Months and older   NCT05286801
PEPN22P1: A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods PEPN22P1 Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Newly diagnosed
Relapsed/Refractory
QLD External
Registry ≫
Open 22/06/2023 Treatment Pilot up to 12 Years NCT05359237
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma AOST2032 High Grade Osteosarcoma
Localized Osteosarcoma
Metastatic Osteosarcoma
Secondary Osteosarcoma
Newly diagnosed NSW / VIC / NZ External
Registry ≫
Open Treatment Phase 2/3 up to 40 Years NCT05691478
T2020-006: A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies T2020-006 Acute lymphoblastic leukemia
Acute myeloid leukemia
Myelodysplastic syndrome
Mixed phenotype acute leukemia
Acute undifferentiated leukemia
Blastic plasmacytoid dendritic cell neoplasm
Hodgkin lymphoma
Non-Hodgkin lymphoma
Relapsed/refractory NSW / VIC External
Registry ≫
Open 11/11/2022 Treatment Phase 1 1 Year to 21 Years NCT05476770
The CLOCK Trial: Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial) The CLOCK Trial All paediatric cancers
Central vascular access device (CVAD) related adverse events
NSW / QLD / VIC External
Registry ≫
Open 10/07/2023 Observational Not applicable 0 Years to 18 Years ACTRN12622000499785
Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia Interfant21 B- precursor acute lymphoblastic leukemia (ALL)
B- cell mixed phenotype acute leukemia (MPAL)
Newly diagnosed NSW / QLD / VIC / WA / SA External
Registry ≫
Open 30/04/2024 Treatment Phase 3 up to 1 Year NCT05327894
ONC201-108: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind Placebo-Controlled Multicenter Study ONC201-108 H3 K27M-mutant diffuse glioma Newly diagnosed NSW / WA / TAS External
Registry ≫
Open Treatment Phase 3 Child, Adult, Older Adult NCT05580562
DEFLEXIFOL (DART): Phase I/II Trial of Deflexifol for Refractory/Recurrent Paediatric Ependymoma DEFLEXIFOL (DART) Ependymoma Relapsed/refractory NSW / QLD / VIC / WA / SA External
Registry ≫
Open 28/08/2023 Treatment Phase 1/2 12 Months to 21 Years ACTRN12623000104651
AAML1831: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations AAML1831 Acute Myeloid Leukemia Newly diagnosed QLD External
Registry ≫
Open 21/07/2020 Treatment Phase 3 up to 21 Years NCT04293562
CBYL719P12201: A Two-stage Double-blind Randomized Placebo-controlled Study to Assess the Efficacy Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Associated Lymphatic Malformations With a PIK3CA Mutation. CBYL719P12201 Lymphatic Malformations Newly diagnosed
Relapsed/Refractory
QLD External
Registry ≫
Open 24/11/2023 Treatment Phase 1/2 2 Years and older NCT05948943 /
P305: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients P305 Haematological diseases New Diagnosis
Relapse/Refractory
VIC External
Registry ≫
Open 17/06/2020 Supportive Care Phase 1 3 months to 18 years ACTRN12620000141943
CLEE011Q12101: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors CLEE011Q12101 Neuroblastoma
Medulloblastoma
High-grade glioma
Malignant rhabdoid tumor
Rhabdomyosarcoma
Relapse/refractory
NSW External
Registry ≫
Open 27/12/2022 Interventional Phase 1/2 12 months to 21 years NCT05429502 /
REGO-EWING: Phase Ib /​ Regorafenib With Conventional Chemotherapy/​Newly Diagnosed Patients/​ Multimetastatic Ewing Sarcoma REGO-EWING Multimetastatic Ewing Sarcoma Newly diagnosed QLD / VIC / WA External
Registry ≫
Open 27/03/2023 Treatment Phase 1 2 Years to 50 Years NCT05830084
INTER-EWING-1: INTERnational scientific program in clinical research to improve outcomes of newly diagnosed EWING sarcoma RG_21-151 (INTER-EWING-1) Ewing Sarcoma Newly Diagnosed VIC / WA / NZ External
Registry ≫
Open 21/06/2024 Treatment Phase 3 ≥2 years ACTRN12624000532505 ISRCTN17938906
OPTIMISE: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer OPTIMISE Bone Cancers
Brain and other CNS Tumours
Germ Cell Tumours
Hodgkin Lymphoma
Kidney (Renal) Tumours
Leukaemia
Liver tumours
Neuroblastoma
Non-Hodgkin Lymphoma
Retinoblastoma
Soft Tissue Sarcomas
Other
Relapsed/Recurrent NSW / QLD / VIC / WA External
Registry ≫
Open 01/03/2024 Treatment Phase 1/2 0 - 21 years NCT06208657
VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas VICTORY Brain and other Central Nervous System (CNS) Tumours
Low Grade Glioma
Relapsed/Recurrent WA External
Registry ≫
Open 23/12/2024 Treatment Pilot Up to 25 Years NCT06381570

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168